Background: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in developing and developed countries. Estimating the total prevalence of NAFLD by means of appropriate statistical methods can provide reliable evidence for health policy makers.
in developed and developing countries [1, 2] . Most of the patients are asymptomatic, while some of them may present with fatigue, dyspepsia, right upper quadrant pain, and hepatosplenomegaly [3] . It has been estimated that NAFLD together with the epidemic of obesity, will be a major cause of liver-associated morbidity and mortality by 2030 [4] .
According to the results of previous studies in different parts of the world, prevalence of NAFLD is 36.8% in Mediterranean region, 5%-24% in China), 20%-40% in Europe, 9%-30% in Japan, 16%-32% in Indian urban areas, and 9% in Indian rural areas. The least prevalence rate in Asian countries is 5% in Singapore [5, 6] .
Prevalence of NAFLD is related to several factors such as age, gender, ethnicity, presence of sleep apnea and endocrine system disorders (e.g., hypothyroidism, hypopituitarism, hypogonadism, and polycystic ovarian syndrome) [3] . It is also strongly associated with obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome [7] . Prevalence of NAFLD increases with age and is more common among males aged 45-65 years. It is also increasing rapidly among children together with obesity epidemics [2] . In one study, the prevalence of NAFLD among obese people is reported as 80%, while only 16% of people with a normal body mass index (BMI) without any metabolic risk factors are suffering from NAFLD [3] . In addition, more than two-third of patients with type 2 diabetes have NAFLD [7] .
Several primary studies have reported different prevalence rates of NAFLD in Iran. Such variation in results makes them inappropriate for policymaking. It is necessary to combine the results of different studies by means of reliable methods [8, 9] . We therefore conducted this study to determine the total prevalence of NAFLD in Iran using a systematic review and meta-analysis.
MAterIAls And Methods

Search Strategy
To find relevant studies published from January 2000 to April 2015, we searched national (SID, Iranmedex, Magiran, and Irandoc) and international (PubMed, Google Scholar, Scopus, and Science Direct) databases using the following keywords and their Persian language equivalents: "prevalence", "NAFLD", "fatty liver disease", "hepatic steatosis", "liver biopsy", "NASH", "ultrasonography", "histopathology", "fibrosis", "liver", "steatosis hepatitis", "non-alcoholic", "sonography", "Iran", "IR Iran", "Persia", "Persian", "Iranian". Boolean operators were used appropriately to manage the search results.
The search was conducted independently by two researchers. We also investigated all references to enhance the search sensitivity. One of the research team members randomly evaluated the results of the search and reported that all relevant studies had been identified. Non-electronic articles were also investigated. To find un-published studies, some relevant research centers as well as experts in the field of our study were interviewed.
Study Selection
We extracted full texts or abstracts of all papers identified during the advanced search. After excluding duplicates, irrelevant studies were omitted reviewing titles, abstracts and full texts, respectively. We also investigated all results in order to remove repeated studies and minimize the probability of reprint bias.
Quality Assessment
Quality of the selected studies was assessed by a previously applied checklist [10] . This checklist used contents of STROBE checklist [11] including 12 questions regarding different aspects of methodology such as type and design of the study, sample size and sampling methods, study population, data collection methods and tools, variables definition, statistical tests, study objectives and presentation of the results according to the objectives. One point was assigned for positive response to each question. Every study with a total sum score of eight or more [10] was considered for the meta-analysis.
Data Extraction
All the required information such as title; first author name; date and place of the study conduction; type of the study; sample size estimation and patient selection; language of the article; diagnostic criteria used for NAFLD (ultrasonography or liver biopsy); prevalence of mild, moderate, and severe fatty liver; association of NAFLD with factors such as patient's sex, age, BMI, systolic and diastolic blood pressure, serum AST, ALT, ALP, TG, FBS, HOMA, LDL, HDL, and total cholesterol; and presence of metabolic syndrome were extracted.
Inclusion Criteria
All studies written in Persian and English with the minimum acceptable quality score and reported sample size, as well as total prevalence of NAFLD (mild, moderate, and severe) were included in the current study.
Exclusion Criteria
Studies that did not report the prevalence of NAFLD or sample size, congress abstracts without full text, case-control studies, clinical trials, and case reports where estimating the prevalence was not possible, and studies with quality scores lower than the accepted minimum value did not further analyzed.
Statistical Analysis
Data analyses were performed using STATA SE ver 11 software. Standard error of the prevalence in each study was calculated assuming binomial distribution of the data. Based on the degree of heterogeneity between the results of the studies (Cochran test and I 2 index), fixed or random effect model was applied to estimate the pooled prevalence of mild, moderate, and severe NAFLD in Iran. In addition, to minimize the random variation between the point estimates of the study results, all results were adjusted using Bayesian analysis. Moreover, sensitivity analysis was used to detect studies influencing the heterogeneity. The point prevalence, weight of each study and 95% confidence interval of the prevalence were illustrated by separate points, sizes of the boxes and crossed lines, respectively.
results
During our primary search in national and international databases, 3389 articles were retrieved. Restricting the search strategy together with excluding duplicates, 269 articles were remained. Screening via titles and abstracts, 183 papers were found irrelevant. Full texts of the rest of articles were investigated; 56 more papers were found irrelevant. After reviewing references, one article was added to the systematic review. Eight articles were removed after quality assessment and 23 studies , were finally found eligible for systematic review and the meta-analysis (Fig 1) .
All articles were published during 2003 to 2015. Of them, 65% were published after 2010. The study design in all of the studies was cross-sectional. Sampling methods were random (10 studies), facilitated (10 studies), or unknown (three studies). Studies were written in English (19 articles) or Persian (four articles). Study populations were general children and young people (five studies), obese children and young people (four studies), general adult population (11 studies) and diabetic patients (three studies). NAFLD had been diagnosed by ultrasonography (21 studies) or liver biopsy (two studies) ( Table 1 ).
The prevalence of fatty liver varied between 2.04%, in a study conducted by Jamali (2008) on 2049 18-75-year-old people selected from general population, and 82.9%, in a study carried out by Hosseinpanah (2007) on 76 patients with diabetes aged 41-83 years. Having adjusted by Bayesian analysis, the corresponding prevalence rates changed to 2.05% and 80.3%, respectively ( Table 2 ).
The prevalence of mild fatty liver reported in 14 studies, varied from 1.2% in a study conducted by Rafeey (2009) on 1500 patients to 58.7% in a study carried out by Razavizadeh (2012) on 254 individuals. The minimum and maximum prevalence rates for moderate fatty Using meta-regression model, study population group was identified as the main source of heterogeneity. The prevalence of NAFLD was increased by 14.7% per one unit increase in the population coding (adult general population: '1,' children general population: '2,' obese children: '3,' and diabetic population: '4').
Although each year increase in the publication age increased the NAFLD prevalence by 1.4%. This association was not statistically significant.
The association between NAFLD and sex was reported in 16 studies, eight of which showed Out of 17 studies reported association between body mass index and NAFLD, 15 studies observed that NAFLD prevalence was increased significantly with BMI. Systolic and diastolic blood pressures were reported to be significantly associated with NAFLD in five out of eight and seven out of nine studies, respectively.
According to the results of 11 studies assessed the association between NAFLD and serum AST level, the association was found significant in four studies. ALT and alkaline phosphatase were also significantly correlated with NAFLD according to the results of eight out of 12 and three out of nine studies, respectively.
The association between NAFLD and serum triglyceride was investigated in 16 studies, 14 of which reported significant results. The corresponding figures for LDL, HDL, and cholesterol were four out of 11 studies, three out of 12 studies, and five out of 14 studies.
Of 11 studies investigated the association between FBS and NAFLD, three studies reported significant associations. All studies reported the significant effects of HOMA (four studies) and metabolic syndrome (three studies) on NAFLD.
It should be noted that due to the low number of studies investigated, the correlations between NAFLD and factors such as job, family history, smoking, hemoglobin concentration, total bilirubin, and direct bilirubin, were not investigated in this systematic review.
dIscussIon
Our meta-analysis showed a pooled total prevalence of NAFLD of 33.95% (Fig 2) . The majority of studies entered in this systematic review, reported that the NAFLD was significantly more common among men (7 of 8 papers), obese people (15 of 15 papers), older ages (10 of 10 papers), patients with systolic hypertension (5 of 8 papers), patients with diastolic hypertension (7 of 9 papers), those with hypertriglyceridemia (14 of 16 papers), high serum HOMA level (4 of 4 papers), patients with metabolic syndrome (4 of 4 papers), and high serum ALT level (8 of 12 papers). Moreover, ultrasonography was the main diagnostic method used for the diagnosis of NAFLD in the studies.
The prevalence of NAFLD among Iranian people has been reported from less than 10% to more than 80% [18, 21] . The prevalence of NAFLD was reported 5%-24% in China, 9%-30% in Japan, 18% in South Korea, 33% in Sri Lanka, 17% in Malaysia, 30% in Indonesia, and 11.5%-42.6% in Taiwan [35] . In a metaanalysis in China the pooled prevalence of NAFLD was estimated at 20.09% [36] . In another study carried out in China, 159 (24.5%) out of 390 healthy people who had undergone ultrasonography, had evidence of fatty liver. These findings were more common among men (27% vs 14%) and those with higher BMI.
In an Indian survey, among 1168 people investigated with ultrasonography, the prevalence of fatty liver was 16.6%-higher in men (24.6%) than women (13.6%). In that study, age >40 years, male gender, central obesity, BMI >25 kg/m 2 , high FBS level, and high serum ALT and AST, were introduced as risk factors of NAFLD [37] .
It has been reported that the prevalence of fatty liver among those living in the territory of Pacific Ocean is 10% so that in some areas, one-third of population have NAFLD. Fatty liver has been reported to be more common among persons with BMI >25 kg/m 2 compared to those with BMI ≤25 kg/m 2 in Taiwan (31% vs 15%, respectively), Japan (60% vs 11%, respectively), and China (39% vs 21%, respectively) [38] . According to the results of another study [38] , the prevalence of fatty liver among American and European general population was more than 45% which was more common among type 2 diabetic patients (50%), obese people (30%-76%), and those with pathological obesity (>98%).
Based on the results of a study conducted in Malaysia on 399 individuals, the prevalence of NAFLD was 49.6%. According to the multivariate analyses, central obesity (OR=2.20) and elevated serum ALT (OR=1.98) were independent risk factors of NAFLD [39] . Another study carried out on 766 Spaniards aged 17-83 years, the prevalence of NAFLD was 25.8%, significantly (p<0.001) more common among men (33.4%) than women (20.3%). Multivariate analysis showed that male gender (OR=2.34), age (OR=1.04), presence of metabolic syndrome (OR=2.19), insulin resistance Xiaona estimated the prevalence of NAFLD among 7152 individuals in Shanghai at 38.17%, which was higher among men increasing with age. In both sexes, prevalence of metabolic factors was higher among those with NAFLD. BMI, waist circumference, weigh:height ratio, blood pressure, blood sugar, total cholesterol, triglyceride, LDL, HDL and uric acid were determinant factors for NAFLD; BMI was the best diagnostic factor for NAFLD. Metabolic factors could increase the risk of NAFLD more than 1.5-3.8 folds [42] .
Results of a Brazilian survey conducted on 1280 patients with NAFLD showed that 66.8% of them had hyperlipidemia, 44.7% obesity, 44.4% overweight, 22.7% suffered from diabetes, and 10% were exposed to poisons. Elevated ALT and AST were observed among 55.8% and 42.2% of patients, respectively. Results of liver biopsy among 437 eligible patients (ALT or AST >1.5 times of normal) consisted of steatosis (42%), osteohepatitis (58%), fibrosis (27%), cirrhosis (15.4%), and hepatocellular carcinoma (0.7%) [43] .
In Brazil, 2.3% of 1801 students, aged 11-18 years, had NAFLD most of them were white males [44] . Other studies reported a prevalence of 77% (China), 28% (Germany), 42%-53%( Italy), and 74% (USA) [45] . Different prevalence rates of NAFLD among Asian countries have been reported such as 56% (Iran), 35% (Korea), 40%-50% (Japan), and 35% (China). It has also been reported as 74% in North America and 70% in Italy. In Mexico, the prevalence among diabetics was more than that of non-diabetics (18.5% vs 7.1%). Another study in India showed that 49% of type 2 diabetic patients had sonographic evidence of fatty liver and prevalence of mild, moderate, or severe NAFLD were 65.5%, 12.5%, and 9.35%, respectively [35] .
In Saudi Arabia, 47.8% of 230 type 2 diabetic patients studied had NAFLD based on abdominal sonography; no significant difference was observed between men (49.1%) and women (46.3%). The prevalence of NAFLD among 40-59-year-old patients was 52.9% [46] .
The above-mentioned results showed that NAFLD risk factors among Iranian population are similar to those of other Islamic countries. However, the results of risk assessments in different Iranian studies were not homogenous making it difficult to determine unique risk factors for NAFLD.
Although liver biopsy is the gold standard for the diagnosis of NAFLD, with a sensitivity of 100% and specificity of 90%, abdominal ultrasonography is the most commonly used method [5, 6] . Another study represented that sonography compared to liver biopsy has 84.8% sensitivity and 93.6% specificity for the diagnosis of moderate to severe fatty liver [2] .
The current systematic review and meta-analysis provided reliable estimates of the prevalence of mild, moderate, and severe NAFLD and determined its risk factors. The high degree of heterogeneity among the results of the studies was one of the main limitations of our study. However, according to a metaregression model, the target population was detected as one of the sources of heterogeneity among primary studies. Moreover, to control this limitation, we applied random effects model to pool the prevalence rates. Therefore, the results should be generalized with caution. Another limitation was inaccessibility to some probable un-published studies. However, we tried to interview with relevant researchers as well as research centers to identify such grey literature.
In conclusion, our study showed that the prevalence of NAFLD in Iran is relatively high; it is associated with male gender, age, obesity, diabetes, metabolic syndrome, hypertension, raised serum ALT and hypertriglyceridemia.
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